Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blinded Extension Study to Evaluate the Long-term Safety and Tolerability of Itepekimab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Participated in Either EFC16750 or EFC16819 Clinical Studies

NCT06208306 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06208306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06208306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blinded Extension Study to Evaluate the Long-term Safety and Tolerability of Itepekimab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Participated in Either EFC16750 or EFC16819 Clinical Studies
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
January 11, 2024
Completion date
September 10, 2026
Enrollment
669 (actual)
Sites
223

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease